Aclaris Therapeutics完成特应性皮炎药物Bosakitug二期临床试验患者招募

美股速递

Mar 18

Aclaris Therapeutics（纳斯达克代码：ACRS）宣布，其用于治疗特应性皮炎的候选药物Bosakitug（研发代号ATI-045）二期临床试验已完成患者入组工作。

临床试验进展提速

本次二期试验旨在评估Bosakitug在中度至重度特应性皮炎患者中的安全性、耐受性及初步疗效。完成患者招募是药物研发过程中的关键里程碑，意味着试验将进入数据收集与分析阶段。若后续数据积极，公司将有望推进至更大规模的三期临床研究。

特应性皮炎治疗市场潜力

特应性皮炎是一种常见的慢性炎症性皮肤病，全球患者基数庞大，且近年发病率呈现上升趋势。目前市场虽已有生物制剂及JAK抑制剂等疗法，但患者对更安全、更便捷的治疗方案仍有显著未满足需求。Bosakitug作为一种局部外用药物，若证实有效，可能提供差异化的治疗选择。

公司研发管线聚焦皮肤病领域

Aclaris Therapeutics是一家专注于免疫炎症性疾病及皮肤病治疗的临床阶段生物制药公司。公司研发策略集中于开发具有新颖作用机制的小分子疗法。Bosakitug的进展是其皮肤病管线推进的重要一步。市场关注后续临床数据的读出时间及结果，这将直接影响公司估值及未来合作开发的可能性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1125195733"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1125195733\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1125195733?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-18 18:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125195733","market":"us","top_or_hot":-1,"title":"Aclaris Therapeutics完成特应性皮炎药物Bosakitug二期临床试验患者招募","media":"美股速递","content":"<p><p>Aclaris Therapeutics（纳斯达克代码：ACRS）宣布，其用于治疗特应性皮炎的候选药物Bosakitug（研发代号ATI-045）二期临床试验已完成患者入组工作。</p></p>\n<p><p><strong>临床试验进展提速</strong></p>\n<p>本次二期试验旨在评估Bosakitug在中度至重度特应性皮炎患者中的安全性、耐受性及初步疗效。完成患者招募是药物研发过程中的关键里程碑，意味着试验将进入数据收集与分析阶段。若后续数据积极，公司将有望推进至更大规模的三期临床研究。</p></p>\n<p><p><strong>特应性皮炎治疗市场潜力</strong></p>\n<p>特应性皮炎是一种常见的慢性炎症性皮肤病，全球患者基数庞大，且近年发病率呈现上升趋势。目前市场虽已有生物制剂及JAK抑制剂等疗法，但患者对更安全、更便捷的治疗方案仍有显著未满足需求。Bosakitug作为一种局部外用药物，若证实有效，可能提供差异化的治疗选择。</p></p>\n<p><p><strong>公司研发管线聚焦皮肤病领域</strong></p>\n<p>Aclaris Therapeutics是一家专注于免疫炎症性疾病及皮肤病治疗的临床阶段生物制药公司。公司研发策略集中于开发具有新颖作用机制的小分子疗法。Bosakitug的进展是其皮肤病管线推进的重要一步。市场关注后续临床数据的读出时间及结果，这将直接影响公司估值及未来合作开发的可能性。</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aclaris Therapeutics完成特应性皮炎药物Bosakitug二期临床试验患者招募</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAclaris Therapeutics完成特应性皮炎药物Bosakitug二期临床试验患者招募\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1004306016\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">美股速递 </p>\n<p class=\"h-time\">2026-03-18 18:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>Aclaris Therapeutics（纳斯达克代码：ACRS）宣布，其用于治疗特应性皮炎的候选药物Bosakitug（研发代号ATI-045）二期临床试验已完成患者入组工作。</p></p>\n<p><p><strong>临床试验进展提速</strong></p>\n<p>本次二期试验旨在评估Bosakitug在中度至重度特应性皮炎患者中的安全性、耐受性及初步疗效。完成患者招募是药物研发过程中的关键里程碑，意味着试验将进入数据收集与分析阶段。若后续数据积极，公司将有望推进至更大规模的三期临床研究。</p></p>\n<p><p><strong>特应性皮炎治疗市场潜力</strong></p>\n<p>特应性皮炎是一种常见的慢性炎症性皮肤病，全球患者基数庞大，且近年发病率呈现上升趋势。目前市场虽已有生物制剂及JAK抑制剂等疗法，但患者对更安全、更便捷的治疗方案仍有显著未满足需求。Bosakitug作为一种局部外用药物，若证实有效，可能提供差异化的治疗选择。</p></p>\n<p><p><strong>公司研发管线聚焦皮肤病领域</strong></p>\n<p>Aclaris Therapeutics是一家专注于免疫炎症性疾病及皮肤病治疗的临床阶段生物制药公司。公司研发策略集中于开发具有新颖作用机制的小分子疗法。Bosakitug的进展是其皮肤病管线推进的重要一步。市场关注后续临床数据的读出时间及结果，这将直接影响公司估值及未来合作开发的可能性。</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACRS","symbol_name":"Aclaris Therapeutics","start_time":0,"source_url":"","article_id":"1125195733","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125195733","pubTimestamp":1773831379,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Aclaris Therapeutics宣布，其用于治疗特应性皮炎的候选药物Bosakitug二期临床试验已完成患者入组工作。本次二期试验旨在评估Bosakitug在中度至重度特应性皮炎患者中的安全性、耐受性及初步疗效。Bosakitug作为一种局部外用药物，若证实有效，可能提供差异化的治疗选择。Aclaris Therapeutics是一家专注于免疫炎症性疾病及皮肤病治疗的临床阶段生物制药公司。Bosakitug的进展是其皮肤病管线推进的重要一步。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"ACRS":"Aclaris Therapeutics","BK4007":"制药"},"translate_title":"Aclaris Therapeutics Completes Patient Recruitment for Phase II Clinical Trial of Atopic Dermatitis Drug Bosakitug","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACRS":1},"content_text":"Aclaris Therapeutics（纳斯达克代码：ACRS）宣布，其用于治疗特应性皮炎的候选药物Bosakitug（研发代号ATI-045）二期临床试验已完成患者入组工作。\n临床试验进展提速\n本次二期试验旨在评估Bosakitug在中度至重度特应性皮炎患者中的安全性、耐受性及初步疗效。完成患者招募是药物研发过程中的关键里程碑，意味着试验将进入数据收集与分析阶段。若后续数据积极，公司将有望推进至更大规模的三期临床研究。\n特应性皮炎治疗市场潜力\n特应性皮炎是一种常见的慢性炎症性皮肤病，全球患者基数庞大，且近年发病率呈现上升趋势。目前市场虽已有生物制剂及JAK抑制剂等疗法，但患者对更安全、更便捷的治疗方案仍有显著未满足需求。Bosakitug作为一种局部外用药物，若证实有效，可能提供差异化的治疗选择。\n公司研发管线聚焦皮肤病领域\nAclaris Therapeutics是一家专注于免疫炎症性疾病及皮肤病治疗的临床阶段生物制药公司。公司研发策略集中于开发具有新颖作用机制的小分子疗法。Bosakitug的进展是其皮肤病管线推进的重要一步。市场关注后续临床数据的读出时间及结果，这将直接影响公司估值及未来合作开发的可能性。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}